Alzor Drug Interactions

Interactions studies have only been performed in adults.
Effects of other medicinal products on Olmesartan medoxomil: Other antihypertensive medications: The blood pressure lowering effect of Olmesartan medoxomil can be increased by concomitant use of other antihypertensive medications.
ACE-inhibitors, angiotensin II receptor blockers or aliskiren: Clinical trial data shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent.
Potassium supplements and potassium sparing diuretics: Based on experience with the use of other drugs that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other drugs that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium. Such concomitant use is therefore not recommended.
Non-steroidal anti-inflammatory drugs (NSAIDs): NSAIDs (including acetylsalicylic acid at doses > 3g/day and also COX-2 inhibitors) and angiotensin-II receptor antagonists may act synergistically by decreasing glomerular filtration.
The risk of the concomitant use of NSAIDs and angiotensin II antagonists is the occurrence of acute renal failure. Monitoring of renal function at the beginning of treatment should be recommended as well as regular hydration of the patient.
Additionally, concomitant treatment can reduce the antihypertensive effect of angiotensin II receptor antagonists, leading to their partial loss of efficacy.
Bile acid sequestering agent colesevelam: Concurrent administration of the bile acid sequestering agent colosevelam hydrochloride reduces the systemic exposure and peak plasma concentration of Olmesartan and reduces t1/2.
Administration of Olmesartan medoxomil at least 4 hours prior to colesevelam hydrochloride decreased the drug interaction effect. Administering Olmesartan medoxomil at least 4 hours before the colesevelam hydrochloride dose should be considered.
Other compounds: After treatment with antacid (aluminium magnesium hydroxide), a modest reduction in bioavailability of Olmesartan was observed.
Effects of Olmesartan medoxomil on other medicinal products: Lithium: Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors and angiotensin II antagonists. Therefore use of Olmesartan medoxomil and lithium in combination is not recommended. If use of the combination proves necessary, careful monitoring of serum lithium levels is recommended.
Other compounds: Compounds which have been investigated in specific clinical studies in healthy volunteers include warfarin, digoxin, an antacid (magnesium aluminum hydroxide), hydrochlorothiazide and pravastin. No clinically relevant interactions were observed and in particular Olmesartan medoxomil had no significant effect on the pharmacokinetics or pharmacodynamics of warfarin or the pharmacokinetics of digoxin.
Olmesartan had no clinically relevant inhibitory effects on in vitro human cytochrome P450 enzymes 1A1/2, 2A6, 2C8/9, 2C19, 2D6, 2E1 and 3A4, and had no or minimal including effects on rat cytochrome P450 activities. Therefore in vivo interaction studies with known cytochrome P450 enzyme inhibitors and inducers were not conducted, and no clinically relevant interactions between Olmesartan and drugs metabolised by the previously mentioned cytochrome P450 enzymes are expected.